SCHEMBL2054699

SCHEMBL2054699

Cn1c(SCC2CC2)nnc1[C@@H](N)CN1CCOCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
KDM4E B2RXH2 5/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
TSHR P16473 2/20 0.36
TP53 P04637 2/20 0.34
LMNA P02545 2/20 0.34
MAPK1 P28482 1/20 0.34
ANPEP P15144 1/20 0.33
NPC1 O15118 1/20 0.32
ABL1 P00519 1/20 0.32
RIN1 Q13671 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
POLB P06746 1/20 0.32
RGS12 O14924 1/20 0.31
HSD17B10 Q99714 1/20 0.31
PABPC1 P11940 1/20 0.31
ALOX15 P16050 1/20 0.31
HSP90AA1 P07900 1/20 0.30
DRD2 P14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2054714 0.79 ALDH1A1 (0.41) ALDH1A1TSHRLMNANPC1L3MBTL1
SCHEMBL2096855 0.79 ALDH1A1 (0.45) ALDH1A1KDM4ECYP3A4CYP2C19TSHR
SCHEMBL2054718 0.76 TSHR (0.38) ALDH1A1KDM4ETSHRTP53LMNA
SCHEMBL8241990 0.75 CYP2C19 (0.47) ALDH1A1KDM4ECYP3A4CYP2C19TSHR
SCHEMBL2054778 0.74 KDM4E (0.33) ALDH1A1KDM4E
SCHEMBL2056443 0.74 KDM4E (0.33) ALDH1A1KDM4E
SCHEMBL2095703 0.71 ALDH1A1 (0.41) ALDH1A1TSHRLMNANPC1L3MBTL1
SCHEMBL2054703 0.69 ALDH1A1 (0.41) ALDH1A1KDM4ETSHRLMNANPC1
SCHEMBL2054710 0.58 ALDH1A1 (0.41) ALDH1A1TSHRTP53POLBHSD17B10
SCHEMBL39809 0.57 USP2 (0.54) ALDH1A1KDM4ELMNAANPEPNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed
WO-2006134341-A1 THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286765-A1 Therapeutic Agents GRIA1, GRIN1, GLRA1 ALDH1A1 652/4885KDM4E 4416/4885CYP3A4 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.